GW Pharmaceuticals plc – NASDAQ:GWPH
GW Pharmaceuticals stock price today
$219.01
+0.04
+0.02%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
GW Pharmaceuticals stock price monthly change
+0.63%
month
GW Pharmaceuticals stock price quarterly change
+2.05%
quarter
GW Pharmaceuticals stock price yearly change
+108.53%
year
GW Pharmaceuticals key metrics
Market Cap | 367.5M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.96 |
Revenue | 559.03M |
EBITDA | -55.48M |
Income | -69.84M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -12.49% |
Oper. margin | -11.73% |
Gross margin | 93.1% |
EBIT margin | -11.73% |
EBITDA margin | -9.93% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGW Pharmaceuticals stock price history
GW Pharmaceuticals stock forecast
GW Pharmaceuticals financial statements
| Jun 2020 | 121.29M | -8.82M | -7.28% |
|---|---|---|---|
| Sep 2020 | 137.05M | -12.18M | -8.89% |
| Dec 2020 | 148.22M | -29.14M | -19.66% |
| Mar 2021 | 152.46M | -19.67M | -12.91% |
| 2020-08-06 | -0.63 | -0.24 |
|---|---|---|
| 2020-11-03 | -0.83 | -0.36 |
| 2021-02-16 | -0.6 | -0.96 |
| 2021-05-03 | -0.36 | -0.05 |
| Jun 2020 | 870580000 | 153.64M | 17.65% |
|---|---|---|---|
| Sep 2020 | 910261000 | 175.81M | 19.31% |
| Dec 2020 | 939511000 | 198.42M | 21.12% |
| Mar 2021 | 934343000 | 197.97M | 21.19% |
| Jun 2020 | -15.74M | -5.92M | -1.43M |
|---|---|---|---|
| Sep 2020 | 1.02M | -3.80M | 746K |
| Dec 2020 | 5.92M | -4.97M | -228K |
| Mar 2021 | -11.72M | -10.82M | -5.60M |
GW Pharmaceuticals other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2020 | 0 | 720000 |
| Jun 2020 | 0 | 18000 |
| Jul 2020 | 0 | 15804 |
| Aug 2020 | 0 | 30000 |
| Sep 2020 | 0 | 14400 |
| Nov 2020 | 0 | 604620 |
| Dec 2020 | 0 | 775464 |
| Jan 2021 | 0 | 810492 |
| Mar 2021 | 0 | 15480 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | KNAPPERTZ VOLKER officer: Chief Me.. | Ordinary Shares | 3,060 | $18.1 | $55,386 | ||
Sale | SNYDER DOUGLAS B. officer: Chief Le.. | Ordinary Shares | 8,400 | N/A | N/A | ||
Sale | BROWN CABOT director | Ordinary Shares | 4,020 | $17.95 | $72,159 | ||
Option | GIACOBELLO SCOTT M. officer: Chief Fi.. | Ordinary Shares | 6,288 | $0 | $6 | ||
Option | GIACOBELLO SCOTT M. officer: Chief Fi.. | Share Options | 6,288 | $0 | $6 | ||
Option | GOVER JUSTIN D. director, officer.. | Ordinary Shares | 17,004 | N/A | N/A | ||
Option | GOVER JUSTIN D. director, officer.. | Share Options | 17,004 | N/A | N/A | ||
Option | KNAPPERTZ VOLKER officer: Chief Me.. | Ordinary Shares | 6,864 | $0 | $7 | ||
Option | KNAPPERTZ VOLKER officer: Chief Me.. | Share Options | 6,864 | N/A | N/A | ||
Option | SNYDER DOUGLAS B. officer: Chief Le.. | Ordinary Shares | 6,636 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q3 2020 3 Nov 2020 | Q3 2020 Earnings Call Transcript |
| Q2 2020 6 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Q1 2020 11 May 2020 | Q1 2020 Earnings Call Transcript |
| Q4 2019 26 Feb 2020 | Q4 2019 Earnings Call Transcript |
Friday, 15 September 2023 | ||
| Monteverde & Associates PC and Kahn Swick & Foti Announce Proposed Class Action Settlement on Behalf of Holders of GW Pharmaceuticals PLC American Depositary Shares | prnewswire.com | |
Tuesday, 19 April 2022 | ||
| Interested in Investing in Psychedelics? Check Out This Podcast. | The Motley Fool |
-
What's the price of GW Pharmaceuticals stock today?
One share of GW Pharmaceuticals stock can currently be purchased for approximately $219.01.
-
When is GW Pharmaceuticals's next earnings date?
Unfortunately, GW Pharmaceuticals's (GWPH) next earnings date is currently unknown.
-
Does GW Pharmaceuticals pay dividends?
No, GW Pharmaceuticals does not pay dividends.
-
How much money does GW Pharmaceuticals make?
GW Pharmaceuticals has a market capitalization of 367.5M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4039.16% to 527.21M US dollars. GW Pharmaceuticals made a loss 58.13M US dollars in net income (profit) last year or -$0.05 on an earnings per share basis.
-
What is GW Pharmaceuticals's stock symbol?
GW Pharmaceuticals plc is traded on the NASDAQ under the ticker symbol "GWPH".
-
What is GW Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—General industry.
-
How do i buy shares of GW Pharmaceuticals?
Shares of GW Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does GW Pharmaceuticals have?
GW Pharmaceuticals plc employs 1,161 workers.
-
When GW Pharmaceuticals went public?
GW Pharmaceuticals plc is publicly traded company for more then 24 years since IPO on 21 Jun 2001.
-
What is GW Pharmaceuticals's official website?
The official website for GW Pharmaceuticals is gwpharm.com.
-
Where are GW Pharmaceuticals's headquarters?
GW Pharmaceuticals is headquartered at Sovereign House, Vision Park, Chivers Way, Cambridge, CAMBRIDGESHIRE.
-
How can i contact GW Pharmaceuticals?
GW Pharmaceuticals's mailing address is Sovereign House, Vision Park, Chivers Way, Cambridge, CAMBRIDGESHIRE and company can be reached via phone at +44 1223 266800.
GW Pharmaceuticals company profile:
GW Pharmaceuticals plc
gwpharm.comExchange:
NASDAQ
Full time employees:
1,161
Industry:
Drug Manufacturers—General
Sector:
Healthcare
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Sovereign House, Vision Park, Chivers Way
Cambridge, CAMBRIDGESHIRE CB24 9BZ
Cambridge, CAMBRIDGESHIRE CB24 9BZ
CIK: 0001351288
ISIN: US36197T1034
CUSIP: 36197T103
